Adrenergic targets for the treatment of cognitive deficits in schizophrenia
- First Online:
- 284 Downloads
The cognitive functions of the prefrontal cortex (PFC) are profoundly impaired in schizophrenic patients. Although dopamine has been the major focus of schizophrenia research, norepinephrine (NE) also has marked influences on PFC cognitive functioning.
This review aims to identify the adrenergic receptors which may be appropriate targets for therapeutic actions in schizophrenia.
Studies of adrenergic mechanisms influencing PFC function in animals and humans were reviewed.
Modest levels of NE engage postsynaptic α2A-adrenergic receptors and strengthen working memory. These beneficial effects have been observed at both the behavioral and cellular levels in animals, and have translated to the clinic in patients with PFC impairments. Thus, the α2A-adrenergic receptor is a proven molecular target. In contrast, high levels of NE released during stress impair PFC cognitive function via activation of protein kinase C intracellular signaling, a pathway increasingly associated with the etiology of schizophrenia. Blockade of α1 adrenoceptors or inhibition of protein kinase C helps to protect PFC cognitive function in animals, and may have similar therapeutic actions in humans. Blockade of the α2C receptor may also be helpful in enhancing catecholamine release while blocking detrimental DA actions in striatum.
Highly selective adrenergic agents may be useful for enhancing PFC function in schizophrenic patients
KeywordsSchizophrenia Cognitive deficit Prefrontal cortex Norepinephrine Adrenergic receptors
- Arnsten AFT (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151–162Google Scholar
- Arnsten AFT, Goldman-Rakic PS (1986) Reversal of stress-induced delayed response deficits in rhesus monkeys by clonidine and naloxone. Soc Neurosci Abstr 12:1464Google Scholar
- Arnsten AFT, Robbins TW (2002) Neurochemical modulation of prefrontal cortical function in humans and animals. In: Stuss DT, Knight RT (eds) Principles of frontal lobe function. Oxford University Press, New York, pp 51–84Google Scholar
- Arnsten AFT, Steere JC, Hunt RD (1996) The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance to attention deficit hyperactivity disorder. Arch Gen Psychiatry 53:448–455Google Scholar
- Duman RS, Nestler EJ (1995) Signal transduction pathways for catecholamine receptors. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, N.Y., pp 303–320Google Scholar
- Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL (2001) Guanfacine treatment of cognitive impairment in schizophrenia: a pilot study. Neuropsychopharmacology (in press)Google Scholar
- Lidow MS (2003) Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res Rev (in press)Google Scholar
- Manji HK et al. (2004) Psychopharmacology (in press)Google Scholar
- Mazure CM (1995) Does stress cause psychiatric illness? In: Spiegel D (ed) Progress in psychiatry. American Psychiatric Press, Washington, D.C., p 270Google Scholar
- Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology:106–118Google Scholar